MicroGen DX

Thank you, ATC 2026.
To every clinician who stopped by Booth 810 to talk about going beyond culture.

What we shared, in lung transplant BAL and pleural fluid:
• 75% combined sensitivity in lung transplant BAL (NGS + culture)
• 3x higher sensitivity vs. standard culture (pleural effusions)
• 89 species identified that standard culture missed

See the research: https://learnmore.microgendx.com/atc26
Sources: Iacono et al., ISHLT 2026; Lopez-Ruiz et al., Am J Respir Crit Care Med 2026.

🧬 ATC 2026, Booth 810.

Bring our CEO a case that culture can't solve.

✓ Sit down with CEO Rick Martin
✓ Bring your toughest culture-negative cases
✓ See where qPCR and Next Generation Sequencing (NGS) reveal the organisms culture leaves behind

📲 Book a meeting: scan the QR code or stop by Booth 810.

https://learnmore.microgendx.com/atc26

Culture comes back negative, but the patient is clearly infected. What guides therapy?

At ATC 2026 we are putting that question to the test: bring our CEO a case culture can't solve.

In a lung transplant BAL cohort (Iacono et al., n = 122, Northwell Health), combined NGS plus culture detected pathogens in 75.0% of specimens versus 51.2% by culture alone (p < 0.0001). In ICU pleural fluid, targeted NGS recovered pathogens that standard culture missed, with specificity preserved.

What every MicroGenDX report delivers:
✓ Species-level identification (16S + ITS)
✓ Up to 17 AMR gene targets via qPCR
✓ Detection that persists under antibiotics
✓ Adjunctive to culture, never a replacement

qPCR + NGS at approximately $400 per test, with Medicare coverage.

Meet our CEO at Booth 810. Boston, June 20-24.

Conference presentation; manuscript in preparation. Numerical findings pending peer-reviewed publication.

https://academic.oup.com/ajrccm/article/212/Supplement_1/aamag162.6017/8686234?guestAccessKey=

hashtag hashtag hashtag hashtag hashtag hashtag